Oculis Holding AG (OCS)
- Previous Close
12.05 - Open
12.01 - Bid 11.99 x 200
- Ask 12.07 x 100
- Day's Range
12.00 - 12.04 - 52 Week Range
9.05 - 14.50 - Volume
88,399 - Avg. Volume
43,388 - Market Cap (intraday)
500.629M - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-3.25 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.44
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
oculis.comRecent News: OCS
Performance Overview: OCS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCS
Valuation Measures
Market Cap
500.63M
Enterprise Value
400.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.60
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.85%
Return on Equity (ttm)
--
Revenue (ttm)
883k
Net Income Avi to Common (ttm)
-88.8M
Diluted EPS (ttm)
-3.25
Balance Sheet and Cash Flow
Total Cash (mrq)
91.65M
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
-24.09M